<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl2">
 <label>Table 2</label>
 <caption>
  <p>Estimates of HDV prevalence in the general population, by WHO region
   <xref rid="tbl2fna" ref-type="table-fn">a</xref>.
  </p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th/>
    <th>AFR</th>
    <th>AMR</th>
    <th>EMR</th>
    <th>EUR</th>
    <th>SEAR</th>
    <th>WPR</th>
    <th>Global</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Population (thousands)</td>
    <td>1,052,766</td>
    <td>1,006,458</td>
    <td>715,425</td>
    <td>928,490</td>
    <td>1,982,239</td>
    <td>1,945,717</td>
    <td>7,631,091</td>
   </tr>
   <tr>
    <td>HBsAg prevalence, % (95% CI)</td>
    <td>6.1 (4.6–8.5)</td>
    <td>0.7 (0.4–1.6)</td>
    <td>3.3 (2.6–4.3)</td>
    <td>1.6 (1.2–2.6)</td>
    <td>2.0 (1.5–4.0)</td>
    <td>6.2 (5.1–7.6)</td>
    <td>3.5 (2.7–5.0)</td>
   </tr>
   <tr>
    <td>Anti-HDV prevalence among people with HBsAg, % (95% CI)</td>
    <td>6.0 (5.0–7.2)</td>
    <td>5.9 (3.0–9.7)</td>
    <td>3.5 (2.1–6.3)</td>
    <td>3.0 (2.1–4.2)</td>
    <td>3.2 (0.4–12.4)</td>
    <td>4.1 (3.5–4.8)</td>
    <td>4.5 (3.6–5.7)</td>
   </tr>
   <tr>
    <td>Anti-HDV prevalence among the general population, % (95% CI)</td>
    <td>0.36 (0.26–0.54)</td>
    <td>0.04 (0.02–0.11)</td>
    <td>0.12 (0.07–0.23)</td>
    <td>0.05 (0.03–0.09)</td>
    <td>0.06 (0.01–0.35)</td>
    <td>0.25 (0.20–0.33)</td>
    <td>0.16 (0.11–0.25)</td>
   </tr>
   <tr>
    <td>HDV RNA prevalence among people with anti-HDV, % (95% CI)</td>
    <td>41.3 (31.8–51.1)</td>
    <td>64.2 (21.5–98.0)</td>
    <td>49.4 (30.1–68.7)</td>
    <td>64.1 (54.3–73.3)</td>
    <td>50.1 (31.4–70.3)</td>
    <td>73.3 (57.8–68.7)</td>
    <td>58.5 (52.4–64.5)</td>
   </tr>
   <tr>
    <td>HDV RNA prevalence among the general population, % (95% CI)</td>
    <td>0.15 (0.10–0.24)</td>
    <td>0.03 (0.01–0.09)</td>
    <td>0.06 (0.03–0.12)</td>
    <td>0.03 (0.02–0.06)</td>
    <td>0.03 (0.00–0.18)</td>
    <td>0.19 (0.13–0.26)</td>
    <td>0.09 (0.07–0.15)</td>
   </tr>
   <tr>
    <td>Number of people with anti-HDV, thousands, % (95% CI)</td>
    <td>3,835 (2,779–5,706)</td>
    <td>416 (185–1,135)</td>
    <td>836 (482–1,610)</td>
    <td>445 (293–833)</td>
    <td>1,267 (172–6,841)</td>
    <td>4,935 (3,836–6,391)</td>
    <td>11,992 (8,662–18,743)</td>
   </tr>
   <tr>
    <td>Number of people with HDV RNA, thousands, (95% CI)</td>
    <td>1,584 (1,059–2,506)</td>
    <td>267 (78–881)</td>
    <td>413 (203–877)</td>
    <td>285 (184–544)</td>
    <td>635 (83–3,622)</td>
    <td>3,617 (2,583–4,971)</td>
    <td>7,015 (4,994–11,109)</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>AFR, African Region; AMR, Region of the Americas; EMR, Eastern Mediterranean Region; EUR, European Region; SEAR, South-East Asian Region; WHO, World Health Organisation; WPR, Western Pacific Region.</p>
  </fn>
 </table-wrap-foot>
 <table-wrap-foot>
  <fn id="tbl2fna">
   <label>a</label>
   <p id="ntpara0010">Sources: Population data for 2018 from UN Population Division World Population Prospects 2019
    <xref rid="bib16" ref-type="bibr">
     <sup>16</sup>
    </xref>; HBV prevalence estimates from WHO Global Hepatitis Report 2017.
    <xref rid="bib1" ref-type="bibr">
     <sup>1</sup>
    </xref>
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
